Healthcare
Japan’s D Capital nears target for debut PE fund
Japan’s D Capital, a private equity firm specialising in digital transformation that spun out from Unison Capital last year, has raised JPY 26bn (USD 188m) for its debut fund against a target of JPY 30bn.
Bain agrees $3b carve-out from Japan's Olympus
Bain Capital has agreed to acquire Evident, a Japan-based medical devices manufacturer best known for producing microscopes, from Olympus Corporation for JPY 427.7bn (USD 3.08bn).
Kedaara buys minority stake in India's Oasis Fertility
Kedaara Capital has invested USD 50m for a significant minority stake in Oasis Fertility, a fertility treatment business with more than 26 centres across India.
Australia's Ramsay Health Care rebuffs revised KKR buyout offer
Australia-listed hospital operator Ramsay Health Care has rejected an alternative buyout proposal from a KKR-led consortium after progress with the initial bid was slowed by the need to conduct due diligence on Ramsay Santé, the company’s separate...
Japan healthcare AI start-up Ubie closes $26m Series C
Japan’s Ubie, a healthcare technology start-up that uses artificial intelligence (AI) for symptom-checking questionnaires, has raised USD 26.2m in Series C funding from local investors.
Korea medical tech start-up raises $20m Series B
Korea’s Airs Medical, a healthcare technology provider active in diagnostics software and robotics, has raised USD 20m in Series B funding from Klim Ventures, Q Capital Partners, and Hanwha Life Insurance.
China Merchants Group backs CDMO player Porton Advanced
Three entities under China Merchants Group (CMG) have led a USD 80m Series B round for Porton Advanced Solutions, a local contract development and manufacturing organisation (CDMO) that focuses solely on gene and cell therapy services.
OTPP to acquire majority stake in India's Sahyadri Hospitals
Ontario Teachers' Pension Plan (OTPP) has agreed its first control private equity buyout in India, taking a majority stake in Sahyadri Hospitals and setting up a partial exit for Everstone Group.
KKR makes $1.2b exit from Indian hospital chain
KKR has exited its entire interest in Indian hospital operator Max Healthcare Institute – nearly four years after assuming control of the business by merging it with an existing portfolio company – with proceeds of approximately INR 91.9bn (USD 1.15bn).
Energy transition case study: Hermina and AIG
Healthcare is not a particularly energy-intensive industry, but specialists such as Quadria Capital are tightening up operations where possible at hospitals
Carlyle backs Japan medical technology player
The Carlyle Group has committed JPY 7bn (USD 52.2m) to CureApp, a Japan-based developer of software for use in the treatment of medical conditions, as part of the company’s Series G round.
Quadria plans full exit through Concord Biotech's India IPO
Singapore-based healthcare specialist Quadria Capital is set for a full exit from pharmaceuticals industry supplier Concord Biotech via an India IPO.
ADIA commits $83m to India's Aditya Birla Health Insurance
Abu Dhabi Investment Authority (ADIA) has agreed to invest INR 6.6bn (USD 83.5m) in India’s Aditya Birla Health Insurance (ADBHI) for a 10% stake.
China's Insilico Medicine gets another $35m
Insilico Medicine, a China-based artificial intelligence-driven drug discovery company, has closed the second tranche of its Series D round on USD 35m, with Prosperity7 Ventures taking the lead.
Navis exits medical cold chain player to US strategic
Navis Capital Partners has sold 100% of B Medical Systems, a Luxembourg-based biotech cold chain provider with significant Asian operations, at an enterprise value of EUR 460m (USD 469m).
Gaorong, Tsing Song back China CDMO IntellectiveBio
Gaorong Capital and Tsing Song Capital have led a CNY 500m (USD 74m) Series C for IntellectiveBio, a China-based contract development and manufacturing organisation (CDMO).
Morningside joins round for China's Epigenic Therapeutics
Morningside Venture Capital has teamed up with Kingray Capital, Trinity Innovation Fund, TigerYeah Capital, and FountainBridge Capital to provide USD 20m in angel and pre-Series A funding for Epigenic Therapeutics, a China-based gene editing specialist.
Australia's Genesis makes biolabs investment
Genesis Capital, a mid-market Australian private equity firm specialising in healthcare, has acquired a majority stake in Crux Biolabs, a contract research organisation (CRO) based in the Melbourne suburbs.
Adamantem to carve out cardiology unit from Australia's GenesisCare
Adamantem Capital has agreed to acquire Australia’s largest cardiology services provider through as a carve-out from KKR-backed healthcare giant GenesisCare.
China biotech company GluBio raises $22m
China and US-based GluBio Therapeutics, which develops targeted protein degradation (TPD) drugs, has raised an extended Series A round of USD22m led by Qiming Venture Partners.
ADIA, GIC lead $300m round for China's Taibang Biologic
Taibang Biologic Group, a specialist in blood plasma-based pharmaceuticals formerly known as China Biologic Products, has raised a USD 300m round led by Abu Dhabi Investment Authority (ADIA) and GIC.
Portfolio: CBC Group and Ensem Therapeutics
CBC Group plans to allocate USD 300m from its latest flagship fund to a biotech incubation platform. Artificial intelligence-enabled drug discovery player Ensem Therapeutics is an example of what it wants to achieve.
China biotech player Sironax raises $200m Series B
Gaorong Capital and Yunfeng Capital have led a USD 200m Series B round for China’s Sironax, a drug developer targeting age-related degenerative diseases.
Qiming, Quan lead $120m Series B for China's OriCell
Qiming Venture Partners and Quan Capital have led a USD 120m Series B round for OriCell Therapeutics, a China-based drug developer that is working on CAR-T cell therapies that target cancer.